Our experts are heading back to Boston for the 4th Annual mRNA Therapeutics Summit. Schedule a meeting now to learn about our end-to-end capabilities for mRNA-based therapeutics.https://ow.ly/tg4150Snrq9 #cdmo #biopharma #pharmaindustry #mRNAbasedtherapeutics #biotech #mRNA #DNA #manufacturing #development #LNPdevelopment #saRNA #lipidsynthesis #fillfinish
Curia’s Post
More Relevant Posts
-
In recent times, the biopharmaceutical sector has seen a surge in the development of oligonucleotides for human medicine, serving both therapeutic and vaccine purposes. These oligonucleotides vary greatly in size and type, including small interfering RNAs (siRNA) and microRNA (miRNA), plasmid DNA (pDNA), as well as messenger RNA (mRNA) vaccines. Discover more about the complexities involved in the analytical testing of oligonucleotide products and the varying degrees of assistance offered by William Boomershine, Ph.D. through his latest whitepaper titled, Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO
To view or add a comment, sign in
-
Today we announced groundbreaking enzymatic synthesis data at the #TIDESUSA annual meeting! Codexis has successfully synthesized a full-length, known siRNA oligonucleotide from starting material through the attachment of a conjugation moiety via an enzymatic route to support RNA-based therapeutics manufacturing. RNAi therapeutics key opinion leader John Maraganore noted, “The data presented today by Codexis are truly unprecedented—I believe this is the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety. This milestone provides meaningful proof of process to industry that there are alternative manufacturing methods available as the demand for RNAi therapeutics increases. The ECO Synthesis™ manufacturing platform has the potential to be a scalable and sustainable way to manufacture this important and growing new class of medicines.” Read our press release for more information: https://lnkd.in/d9WquAUY #enzymeengineering #proteinengineering #RNAi #RNAimanufacturing #enzymaticsynthesis
To view or add a comment, sign in
-
🔬 Discover the cutting-edge advancements in bi-specific antibody (#bsAb) therapeutics in GenScript's upcoming webinar. Learn about their diverse architectures and the innovative strategies used in their production. Bi-specific antibodies (bsAbs) target two different antigens or epitopes, showing great promise in enhancing drug efficacy. Optimizing bsAb purification is challenging due to their unique structures, but this webinar will provide valuable insights and solutions 🌟 The expert speaker, Rob Ford, will guide you through the various bsAb architectures and production strategies! 👉 Learn more and register here: https://buff.ly/3wBMlbY #DrugDevelopment #DrugDiscovery #CellTherapy #Biotherapeutics #MonoclonalAntibodies #MonoclonalAntibody #BasicResearch #BispecificAntibody
To view or add a comment, sign in
-
When considering new clinical targets, #formulations, and delivery methods for #RNA-based therapeutics, you need a comprehensive view of the IP landscape to protect your investments. Read our new executive summary to explore #IP trends and opportunities in this space. https://ow.ly/JXk550QLFnn
To view or add a comment, sign in
-
If you're in the process of developing antibody therapeutics and are still in discovery mode, #Lonza has the perfect solution for you! Our GS System® offers the same host cell, transposon, and vector system from discovery through CMC and on to commercial supply. This means a seamless process from start to finish, which means reduced costs and time savings. If you're interested in learning more about how we can help on your drug discovery journey, let's discuss! #antibodytherapeutics #drugdiscovery #biopharmaceuticals
To view or add a comment, sign in
-
In recent times, the biopharmaceutical sector has seen a surge in the development of oligonucleotides for human medicinal applications, spanning both therapeutic uses and vaccine formulations. This category includes a diverse array of entities such as small interfering RNAs (siRNA) and microRNA (miRNA), along with plasmid DNA (pDNA) and messenger RNA (mRNA) vaccines. Discover the intricacies involved in the analytical testing of oligonucleotide products and explore the varying degrees of assistance provided by William Boomershine, Ph.D. through his latest whitepaper titled, Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO
To view or add a comment, sign in
-
In recent years, the biopharmaceutical sector has seen an expansive development of oligonucleotides as human medications, serving both therapeutic and vaccine purposes. This category includes a diverse array of products such as small interfering RNAs (siRNA) and microRNA (miRNA), plasmid DNA (pDNA), and messenger RNA (mRNA) vaccines. Discover the intricacies involved in the analytical testing of oligonucleotide products and the varying degrees of support provided by William Boomershine, Ph.D., in his latest whitepaper titled Navigating the Analytical Complexity of Oligonucleotide Therapeutics ➡️https://gag.gl/n2bMIO #labservices #askalcami #alcami #oligonucleotide #analytical #CDMO
To view or add a comment, sign in
-
Caring for patients by making tomorrow's Biologics medicines in partnership 🤝; an inter-disciplinary translator;🚶🏻✝️; 🚵♀️; Opinions are only mine😉
What's the state of the commercial R&D #antibodydrugconjugates space? The Antibody Society has just released its summary of the commercial antibody therapeutics pipeline that they carefully manually curate. Having reviewed it I've summarised over 400 ADCs and RITs that have been or are in commercial R&D up to Oct 2023. Key insight: It's a competitive space, around relatively few targets with a substantial risk of termination. It's exciting and competitive times for those of us driving #antibodydrugconjugates #scienceandtechnology #innovation #precisionmedicine #pharmacology to help transform patients' lives. The first three rows in the table correspond to the graphs in descending order.
To view or add a comment, sign in
-
With the Biopharma industry starting to build a stronger understanding around the needs and assessments of their mRNA therapeutics, one of the biggest impacts that have been uncovered is the importance of Poly(A) tail length determination and how it effects efficiency and stability of your final product. In the technote below, the SCIEX tech team has developed a simplified workflow for Poly(A) tail analysis to achieve single base resolution for accurate sizing determination on our PA800 plus system. Take a look at this outstanding workflow for a valuable CQA in mRNA assessment! #SCIEX #CE #biopharma #pharma #biotechnology #mRNA #RNA
To view or add a comment, sign in
-
Learn about enabling robust mRNA production with end-to-end in-process analytics. Join our lecture on July 29 at the 4th mRNA-Based Therapeutics Summit. Register now: https://sar.to/qteta #SimplifyingProgress #InThisTogether #Chromatography
To view or add a comment, sign in
81,049 followers